Cargando…
Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs
Neglected diseases caused by arenaviruses such as Lassa virus (LASV) and filoviruses like Ebola virus (EBOV) primarily afflict resource-limited countries, where antiviral drug development is often minimal. Previous studies have shown that many approved drugs developed for other clinical indications...
Autores principales: | Herring, Shawn, Oda, Jessica M., Wagoner, Jessica, Kirchmeier, Delaney, O’Connor, Aidan, Nelson, Elizabeth A., Huang, Qinfeng, Liang, Yuying, DeWald, Lisa Evans, Johansen, Lisa M., Glass, Pamela J., Olinger, Gene G., Ianevski, Aleksandr, Aittokallio, Tero, Paine, Mary F., Fink, Susan L., White, Judith M., Polyak, Stephen J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097473/ https://www.ncbi.nlm.nih.gov/pubmed/33468464 http://dx.doi.org/10.1128/AAC.01146-20 |
Ejemplares similares
-
The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus
por: Georgi, Fanny, et al.
Publicado: (2020) -
Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C
por: Ulferts, Rachel, et al.
Publicado: (2016) -
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
por: Jeon, Sangeun, et al.
Publicado: (2020) -
Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection
por: Burdette, Dara, et al.
Publicado: (2022) -
Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages
por: Sake, Svenja M., et al.
Publicado: (2022)